| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Research and development | 27,094 | |||
| General and administrative | 4,404 | |||
| Total operating expenses | 31,498 | |||
| Loss from operations | -31,498 | |||
| Interest income | 1,549 | |||
| Other income, net | 531 | |||
| Total other income, net | 2,080 | |||
| Net loss | -29,418 | |||
| Earnings per share, basic | -37.18 | |||
| Earnings per share, diluted | -37.18 | |||
| Weighted average number of shares outstanding, diluted | 791,127 | |||
| Weighted-average common stock outstanding - basic | 791,127 | |||
MapLight Therapeutics, Inc. (MPLT)
MapLight Therapeutics, Inc. (MPLT)